<DOC>
	<DOCNO>NCT02014142</DOCNO>
	<brief_summary>Determine efficacy latanoprost punctal plug . Effect configuration L-PPDS placement efficacy also examine .</brief_summary>
	<brief_title>A Phase 2 Single-Masked , Randomized Study Latanoprost PPDS Ocular Hypertension Open-Angle Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<criteria>1 . Male female , 18 year old time screen examination 2 . Subject diagnosed bilateral OAG OH 3 . Subject IOP currently control ( &lt; 21 mmHg ) topical prostaglandin conjunction one topical ocular hypotensive drug , include fixedcombination formulation ( i.e. , Cosopt , Combigan , Azarga , etc . ) least one month 4 . Subject low upper puncta &gt; 0.5 mm &lt; 0.9 mm ( predilation ) eye 5 . Subject must able willing read , comprehend give Authorization Use/Disclosure Health Information ( HIPAA ) inform consent 6 . Subject must willing comply study instruction , dose ( applicable ) , agree make office appointment , complete entire course study 7 . Women childbearing potential must pregnant lactating , must negative pregnancy test screening must practice adequate method birth control , include intrauterine device ( IUD ) ; oral , dermal ( `` patch '' ) , implant injected contraceptive ; tubal ligation ; barrier method spermicide 8 . Subject central corneal thickness &gt; 500 μm &lt; 600 μm study eye 9 . Subject BCVA pinhole visual acuity ( Snellen ) 20/100 good eye 1 . Subject history nonresponse topical prostaglandin eye drop OAG/OH 2 . Subject angleclosure glaucoma , neovascular glaucoma , traumatic glaucoma iridocorneal endothelium syndrome either eye 3 . Subject know sensitivity latanoprost , timolol , fluorescein , topical anesthetic , silicone , inactive ingredient LPPDS product require study procedures 4 . Subject history intolerance topical betablocker therapy 5 . Subject &gt; 0.8 vertical cup completely notch optic nerve head rim either eye 6 . Subject functionally significant visual field loss progressive field loss within last year either eye 7 . Subject history complication , AEs , trauma disease nasolacrimal area , whether due punctal plug wear , include limited dacryocystitis , inflammation canaliculitis study eye 8 . Subject structural lid abnormality ( i.e. , ectropion , entropion ) study eye 9 . Subject active lid disease either eye ( i.e. , moderate severe blepharitis , meibomianitis ) require medical treatment 10 . Subject history chronic/recurrent inflammatory eye disease ( i.e. , scleritis , uveitis , herpes keratitis ) either eye 11 . Subject would require use ocular topical medication ( ) , overthe counter drop ( ) , ointment ( ) gel ( ) , study ocular hypotensive medication ( ) either eye study period 12 . Subject ophthalmic surgical procedure ( i.e. , glaucoma laser , minimally invasive glaucoma surgery , cataract , refractive , etc . ) study eye within last six month require ophthalmic surgery complete study 13 . Subject history penetrate keratoplasty study eye 14 . Subject incapable instill ocular drop eyes 15 . Subject require use contact lens either eye time study period 16 . Subject advance diabetic retinopathy , branch retinal vein occlusion central retinal vein occlusion either eye 17 . Subject history macular edema either eye 18 . Subject currently systemic medication [ i.e. , betablocker , carbonic anhydrase inhibitor , corticosteroid ( include dermal ) , etc . ] , may effect subject 's IOP , require use study period ( Note : inhale steroid , systemic betablocker βadrenoceptor antagonist may permit , provide subject maintain stable dosage regimen least last three month ) 19 . Subject contraindicate therapy betablocker ( i.e. , history presence bradycardia , untreated congestive heart failure , untreated second thirddegree heart block , sinoatrial block , myasthenia gravis , cardiogenic shock , history presence bronchial asthma , bronchial hyperreactivity , severe chronic obstructive pulmonary disease , history bronchospasm ) 20 . Subject uncontrolled systemic disease medical condition may increase risk associate study participation administration study treatment may interfere interpretation study result ( e.g. , autoimmune disease subject chronic medication ocular involvement ; hostversusgraft disease ) 21 . Subject currently participate participate within last 30 day prior start study drug , device investigational research study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>